Showing results (101-110 of 128) with videos related to
Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2025
Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA StudyPeter A Fasching, Sabine Schmatloch, Jan Hauke, et al.European Journal of Cancer (Oxford, England : 1990)|August 27, 2021
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Gene Expression-Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION TrialKarolina Edlund, Katrin Madjar, Antje Lebrecht, et al.Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|April 18, 2023
Best Practice Guideline - DEGUM Recommendations on Breast UltrasoundClaudia Maria Vogel-Minea, Werner Bader, Jens-Uwe Blohmer, et al.Cancers|April 3, 2021
Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA StudyMaggie Banys-Paluchowski, Maria Luisa Gasparri, Jana de Boniface, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2025
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast CancerFabio Conforti, Valentina Nekljudova, Isabella Sala, et al.The Lancet. Oncology|November 27, 2025
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trialsFabio Conforti, Johannes Holtschmidt, Valentina Nekljudova, et al.The Lancet. Oncology|July 12, 2021
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trialsCarsten Denkert, Fenja Seither, Andreas Schneeweiss, et al.Cancer Prevention Research (Philadelphia, Pa.)|November 22, 2024
Calculating Future 10-Year Breast Cancer Risks in Risk-Adapted Surveillance: A Method Comparison and Application in Clinical PracticeSilke Zachariae, Anne S Quante, Marion Kiechle, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumorsMarcus Schmidt, Birte Hellwig, Seddik Hammad, et al.Pageof 13